

# Kwang-Hyub Han

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9077280/publications.pdf>

Version: 2024-02-01

460  
papers

28,026  
citations

13854

67  
h-index

8156

148  
g-index

474  
all docs

474  
docs citations

474  
times ranked

21966  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 1163-1173.	6.3	3,542
2	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
3	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1001-1010.	13.9	1,345
4	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	1.9	874
5	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 886-893.	3.6	840
6	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. <i>Hepatology International</i> , 2008, 2, 263-283.	1.9	832
7	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2015, 16, 1344-1354.	5.1	809
8	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	1.8	734
9	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology, The</i> , 2011, 12, 568-574.	5.1	541
10	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , 2011, 31, 61-80.	1.9	481
11	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894.	3.6	329
12	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 133, 1437-1444.	0.6	324
13	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 167-228.	3.7	320
14	Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). <i>Journal of Hepatology</i> , 2015, 63, 486-493.	1.8	264
15	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , 2016, 63, 776-786.	3.6	261
16	Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44930.	1.1	242
17	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015, 62, S144-S156.	1.8	239
18	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1382-1390.	0.2	194

#	ARTICLE	IF	CITATIONS
19	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. <i>Journal of Hepatology</i> , 2017, 66, 910-918.	1.8	192
20	Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2005, 42, 188-194.	1.8	191
21	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	4.2	172
22	Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI?. <i>European Radiology</i> , 2009, 19, 1744-1751.	2.3	158
23	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	1.8	148
24	Epidemiology and Surveillance of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 2-14.	4.2	144
25	Controlled attenuation parameter (<scp>CAP</scp>) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109.	1.9	143
26	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2008, 113, 995-1003.	2.0	138
27	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean. <i>PLoS ONE</i> , 2012, 7, e39175.	1.1	137
28	Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. <i>Oncology</i> , 2013, 84, 311-318.	0.9	134
29	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	1.8	131
30	MRP2 haplotypes confer differential susceptibility to toxic liver injury. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 403-415.	0.7	127
31	Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. <i>Gastroenterology</i> , 2014, 146, 442-452.e1.	0.6	123
32	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763.	1.1	122
33	The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 556-563.	1.8	122
34	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	3.6	121
35	Association between hepatitis B virus infection and HLA-DR type in Korea. <i>Hepatology</i> , 2000, 31, 1371-1373.	3.6	120
36	Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. <i>Hepatology</i> , 2011, 53, 1486-1493.	3.6	120

#	ARTICLE	IF	CITATIONS
37	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.2	120
38	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Carcinogenesis</i> , 2008, 29, 1192-1196.	1.3	119
39	Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. <i>Hepatology</i> , 2015, 61, 1809-1820.	3.6	117
40	Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study. <i>Yonsei Medical Journal</i> , 2005, 46, 399.	0.9	109
41	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 415-421.	3.6	107
42	Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. <i>Oncology</i> , 2011, 81, 158-164.	0.9	104
43	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2007, 110, 129-137.	2.0	102
44	Role of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma. <i>Oncology</i> , 2007, 72, 104-110.	0.9	101
45	Serotonin signals through a gut-liver axis to regulate hepatic steatosis. <i>Nature Communications</i> , 2018, 9, 4824.	5.8	98
46	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	3.6	97
47	Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 969-976.	1.9	96
48	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71.	1.1	94
49	New Automated Hepatitis C Virus (HCV) Core Antigen Assay as an Alternative to Real-Time PCR for HCV RNA Quantification. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2253-2256.	1.8	91
50	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	1.9	91
51	Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1682-1691.	1.1	90
52	Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. <i>Journal of Hepatology</i> , 2016, 64, 618-627.	1.8	88
53	Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis. <i>Cell Transplantation</i> , 2010, 19, 1237-1246.	1.2	84
54	Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e36676.	1.1	84

#	ARTICLE	IF	CITATIONS
55	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1343-1350.	1.9	83
56	Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 543-548.	3.2	82
57	Outcome after curative resection for a huge (≈10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. <i>American Journal of Surgery</i> , 2009, 198, 693-701.	0.9	82
58	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , 2013, 33, 586-594.	1.9	81
59	Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1621-1630.	3.3	79
60	Long-term outcome of chronic hepatitis B based on histological grade and stage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 383-388.	1.4	79
61	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839.	2.3	78
62	Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , 2008, 2, 471-7.	1.9	77
63	What are "true normal" liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274.	1.9	76
64	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	1.9	76
65	Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization. <i>Antiviral Therapy</i> , 2005, 10, 441-449.	0.6	73
66	Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. <i>Laboratory Investigation</i> , 2006, 86, 676-686.	1.7	71
67	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	1.3	71
68	Transforming Growth Factor- $\beta$ Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail. <i>Gastroenterology</i> , 2017, 153, 1378-1391.e6.	0.6	71
69	Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286.	0.7	70
70	Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 131, 81-87.	0.3	70
71	Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 279.	4.5	70
72	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68

#	ARTICLE	IF	CITATIONS
73	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.2	68
74	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384.	1.2	67
75	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014, 63, 996-1004.	6.1	67
76	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 855-862.	1.8	67
77	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255.	1.9	66
78	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 955-961.	1.4	65
79	CD11b <sup>+</sup> Gr1 <sup>+</sup> bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. <i>Hepatology</i> , 2012, 56, 1902-1912.	3.6	65
80	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4001-4001.	0.8	65
81	Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 235-241.	0.6	64
82	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	1.9	64
83	Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964.	1.1	64
84	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358.	1.1	62
85	Prognostic value of Î±-fetoprotein and des-Î³-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , 2013, 13, 5.	1.1	60
86	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575.	1.3	59
87	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw507.	2.9	58
88	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 659-667.	1.2	57
89	Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1384-1390.	1.4	57
90	Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. <i>Liver International</i> , 2015, 35, 1103-1115.	1.9	57

#	ARTICLE	IF	CITATIONS
91	Prognostic value of 18Fâ€¦FDG PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , 2011, 31, 1144-1149.	1.9	56
92	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.2	56
93	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 457-467.e21.	2.4	56
94	Early Î±-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 369-376.	1.9	55
95	Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 23-31.	1.5	55
96	Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 130-136.	1.4	53
97	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	0.7	53
98	Liver stiffness measurement using FibroScan <sup>®</sup> is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , 2009, 29, 810-815.	1.9	51
99	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 335-348.	1.4	51
100	Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 219.	1.4	51
101	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2009, 81, 1002-1008.	2.5	50
102	How to Predict HCC Development in Patients with Chronic B Viral Liver Disease?. <i>Intervirology</i> , 2005, 48, 23-28.	1.2	49
103	Impact of Hepatitis B Virus (HBV) X Gene Mutations on Hepatocellular Carcinoma Development in Chronic HBV Infection. <i>Vaccine Journal</i> , 2011, 18, 914-921.	3.2	49
104	The Accuracy of Noninvasive Methods in Predicting the Development of Hepatocellular Carcinoma and Hepatic Decompensation in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 518-525.	1.1	49
105	Discordance between Liver Biopsy and FibroScan <sup>®</sup> in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation. <i>PLoS ONE</i> , 2012, 7, e32233.	1.1	49
106	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162.	0.4	49
107	Clinical outcome of renal transplantation in patients with positive preâ€¦transplant hepatitis B surface antigen. <i>Journal of Medical Virology</i> , 2007, 79, 1655-1663.	2.5	48
108	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158.	1.4	48

#	ARTICLE	IF	CITATIONS
109	<sup>18</sup> Fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	2.0	47
110	Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. <i>Journal of Gastroenterology</i> , 2013, 48, 681-688.	2.3	47
111	New Diagnostic Method for Liver Fibrosis and Cirrhosis. <i>Intervirolgy</i> , 2008, 51, 11-16.	1.2	46
112	Efficacy of adefovir on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2010, 82, 1835-1842.	2.5	46
113	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	1.8	46
114	Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1954-1963.e3.	2.4	46
115	Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis Research and Therapy</i> , 2012, 14, R232.	1.6	45
116	Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825.	1.1	45
117	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1850-1859.e4.	2.4	45
118	Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1008-1017.	1.9	44
119	Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. <i>Journal of Hepatology</i> , 2019, 71, 289-300.	1.8	44
120	Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 485-493.	1.9	43
121	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	1.9	43
122	Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , 2010, 4, 673-680.	1.9	42
123	Comparison of Surrogate Serum Markers and Transient Elastography (Fibroscan) for Assessing Cirrhosis in Patients with Chronic Viral Hepatitis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3552-3560.	1.1	42
124	Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.4	42
125	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: A multicenter, prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 171-178.	1.4	42
126	Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. <i>Oncology</i> , 2011, 81, 41-49.	0.9	42



#	ARTICLE	IF	CITATIONS
127	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544.	1.1	42
128	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891.	0.2	42
129	Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , 2018, 25, 3308-3315.	0.7	42
130	Hepatocellular carcinoma in Budd-Chiari syndrome: A single center experience with long-term follow-up in South Korea. <i>World Journal of Gastroenterology</i> , 2012, 18, 1946.	1.4	42
131	Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 445-451.	0.4	41
132	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , 2012, 13, 47.	2.1	40
133	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia. <i>PLoS ONE</i> , 2014, 9, e86449.	1.1	40
134	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , 2010, 51, 767-776.	3.6	39
135	Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. <i>Yonsei Medical Journal</i> , 2016, 57, 1276.	0.9	39
136	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. <i>Clinical Cancer Research</i> , 2021, 27, 4848-4858.	3.2	39
137	Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 40756-40766.	0.8	39
138	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	0.6	38
139	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	3.2	38
140	Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1595-1605.	1.2	38
141	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014, 32, 4006-4006.	0.8	38
142	Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. <i>Journal of Hepatology</i> , 2001, 35, 92-98.	1.8	37
143	Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , 2006, 78, 1564-1571.	2.5	37
144	Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: Culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 122-128.	1.4	37

#	ARTICLE	IF	CITATIONS
145	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919.	3.6	37
146	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. <i>Hepatology International</i> , 2016, 10, 883-892.	1.9	37
147	Validation of <sc>PAGE</sc>â€ model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	1.9	37
148	<i>Wisteria floribunda</i> agglutininâ€positive human Macâ€2 binding protein predicts the risk of <sc>HBV</sc>â€related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887.	1.9	37
149	Gammaâ€glutamyl transpeptidaseâ€toâ€platelet ratio is an independent predictor of hepatitis B virusâ€related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229.	1.4	37
150	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	1.7	37
151	Natural history of hepatitis B virusâ€related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727.	1.4	36
152	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. <i>Experimental and Molecular Medicine</i> , 2011, 43, 341.	3.2	36
153	Impact of Spontaneous Hepatocellular Carcinoma Rupture on Recurrence Pattern and Longâ€term Surgical Outcomes after Partial Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 2070-2078.	0.8	36
154	Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 495-501.	0.6	36
155	Conventional versus drugâ€eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	1.4	36
156	Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. <i>Journal of Medical Virology</i> , 2003, 71, 367-375.	2.5	35
157	Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. <i>Liver International</i> , 2005, 25, 1197-1201.	1.9	35
158	Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 861-866.	0.6	35
159	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. <i>Liver International</i> , 2010, 30, 1427-1438.	1.9	35
160	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856.	0.8	35
161	Combined measurement of preoperative Î±â€fetoprotein and desâ€Î³â€carboxy prothrombin predicts recurrence after curative resection in patients with hepatitisâ€Bâ€related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 2332-2341.	2.3	35
162	High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 581.	1.8	35

#	ARTICLE	IF	CITATIONS
163	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 186-186.	0.8	35
164	Hepatic Splenosis Preoperatively Diagnosed as Hepatocellular Carcinoma in a Patient with Chronic Hepatitis B: A Case Report. <i>Journal of Korean Medical Science</i> , 2008, 23, 336.	1.1	34
165	Liver stiffnessâ€based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	1.9	34
166	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	1.1	34
167	Emerging Therapies for Hepatitis C. <i>Gut and Liver</i> , 2014, 8, 471-479.	1.4	34
168	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296.	0.9	33
169	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	1.1	33
170	Changes in Serum and Ascitic Monocyte Chemotactic Protein-1 (MCP-1) and IL-10 Levels in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 227-230.	0.5	32
171	Efficacy and Safety of Transarterial Chemoembolization in Recurrent Hepatocellular Carcinoma After Curative Surgical Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 564-569.	0.6	32
172	Predictive value of <sc>HBsAg</sc> quantification for determining the clinical course of genotype C <sc>HBsAg</sc>â€negative carriers. <i>Liver International</i> , 2012, 32, 796-802.	1.9	32
173	Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging. <i>PLoS ONE</i> , 2013, 8, e59869.	1.1	32
174	Longâ€term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	1.9	32
175	A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009.	1.1	32
176	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6.	2.4	32
177	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39.	0.8	32
178	Molecular and clinical characteristics of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , 2010, 82, 1126-1134.	2.5	31
179	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , 2010, 30, 1073-1081.	1.9	31
180	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885.	0.9	31

#	ARTICLE	IF	CITATIONS
181	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	4.5	31
182	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	4.5	31
183	The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 447-455.	0.6	31
184	Predictive Value of Liver Cell Dysplasia for Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 738-743.	1.1	30
185	Transient elastography in chronic hepatitis B: An Asian perspective. <i>World Journal of Gastroenterology</i> , 2010, 16, 5173.	1.4	30
186	Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322.	1.4	30
187	Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 1-8.	0.3	30
188	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	1.1	30
189	Ascites and spontaneous bacterial peritonitis: An Asian perspective. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1494-1503.	1.4	29
190	Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788.	1.4	29
191	Clinical usefulness of double biomarkers <sc>AFP</sc> and <sc>PIVKA-II</sc> for subdividing prognostic groups in locally advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 313-321.	1.9	29
192	Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. <i>PLoS ONE</i> , 2017, 12, e0167770.	1.1	29
193	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	1.9	29
194	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542.	1.4	28
195	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328.	0.4	28
196	A phase 3b study of sofosbuvir plus ribavirin in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 358-365.	1.0	28
197	Cryoablation of Hepatocellular Carcinoma with High-Risk for Percutaneous Ablation: Safety and Efficacy. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1447-1454.	0.9	28
198	The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size. <i>Journal of Korean Medical Science</i> , 2009, 24, 242.	1.1	27

#	ARTICLE	IF	CITATIONS
199	Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea. <i>Yonsei Medical Journal</i> , 2011, 52, 753.	0.9	27
200	Usefulness of Positron Emission Tomography With Fluorine-18-Fluorodeoxyglucose in Predicting Treatment Response in Unresectable Hepatocellular Carcinoma Patients Treated With External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1172-1178.	0.4	27
201	Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 1178.	0.9	27
202	Inhibition of tumour angiogenesis and growth by small hairpin $\langle \text{scp} \rangle \text{HIF} \langle / \text{scp} \rangle$ and $\langle \text{scp} \rangle \text{IL} \langle / \text{scp} \rangle$ in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642.	1.9	27
203	Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2013, 8, e69166.	1.1	26
204	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	1.4	26
205	Therapeutic benefit of radiotherapy in huge ( $\geq 10 \text{ cm}$ ) unresectable hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 784-794.	1.9	26
206	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy. <i>International Journal of Cancer</i> , 2016, 138, 1601-1608.	2.3	26
207	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 317-317.	0.8	26
208	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. <i>Antiviral Therapy</i> , 2009, 14, 705-712.	0.6	26
209	Surgical resection for pulmonary metastasis from hepatocellular carcinoma: Analysis of prognosis in relation to primary control. <i>Journal of Surgical Oncology</i> , 2010, 101, 239-243.	0.8	25
210	Current Situation of Hepatocellular Carcinoma in Mongolia. <i>Oncology</i> , 2011, 81, 148-151.	0.9	25
211	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884.	1.1	25
212	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. <i>PLoS ONE</i> , 2015, 10, e0139227.	1.1	25
213	The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. <i>Annals of Nuclear Medicine</i> , 2015, 29, 400-408.	1.2	25
214	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	1.3	25
215	Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. <i>Antiviral Therapy</i> , 2005, 10, 441-9.	0.6	25
216	Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. <i>PLoS ONE</i> , 2014, 9, e99167.	1.1	24

#	ARTICLE	IF	CITATIONS
217	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 272-278.	1.1	24
218	Early $\alpha$ -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 39.	1.8	24
219	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. <i>Oncotarget</i> , 2017, 8, 113213-113224.	0.8	24
220	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 828-834.	1.4	24
221	Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 503-510.	1.4	24
222	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1.	2.4	24
223	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. <i>PLoS ONE</i> , 2017, 12, e0187066.	1.1	24
224	Hepatitis C Virus and Antiviral Drug Resistance. <i>Gut and Liver</i> , 2016, 10, 890-895.	1.4	24
225	Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon- $\alpha$ therapy. <i>Journal of Medical Virology</i> , 1996, 49, 95-102.	2.5	23
226	Preoperative Radiologic and Postoperative Pathologic Risk Factors for Early Intra-Hepatic Recurrence in Hepatocellular Carcinoma Patients Who Underwent Curative Resection. <i>Yonsei Medical Journal</i> , 2009, 50, 789.	0.9	23
227	Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. <i>Medicine (United States)</i> , 2016, 95, e2985.	0.4	23
228	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , 2017, 11, 268-276.	1.9	23
229	Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: A randomized prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1215-1222.	1.4	22
230	Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. <i>Hepatology International</i> , 2012, 6, 763-769.	1.9	22
231	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , 2013, 6, 1463.	1.0	22
232	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for $\alpha$ -fetoprotein; hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 347.	1.0	22
233	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	1.9	22
234	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	1.9	22

#	ARTICLE	IF	CITATIONS
235	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2019, 121, 218-221.	2.9	22
236	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	1.4	22
237	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984.	0.8	22
238	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847.	1.4	21
239	Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. <i>Anticancer Research</i> , 2011, 31, 4641-6.	0.5	21
240	Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	0.6	20
241	Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191.	0.9	20
242	Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. <i>Digestion</i> , 2012, 85, 219-227.	1.2	20
243	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	1.1	20
244	Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years. <i>World Journal of Surgical Oncology</i> , 2014, 12, 192.	0.8	20
245	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	1.9	20
246	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. <i>Liver International</i> , 2016, 36, 1108-1115.	1.9	20
247	Effect of S267F variant of NTCP on the patients with chronic hepatitis B. <i>Scientific Reports</i> , 2017, 7, 17634.	1.6	20
248	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	1.6	20
249	Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 33-44.	4.5	20
250	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	4.5	20
251	Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. <i>Cancer Research and Treatment</i> , 2016, 48, 1243-1252.	1.3	20
252	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774.	1.4	20

#	ARTICLE	IF	CITATIONS
253	Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 729-735.	1.4	19
254	Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. <i>Journal of Medical Virology</i> , 2009, 81, 594-601.	2.5	19
255	Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , 2009, 29, 760-766.	1.9	19
256	The significance of ICG-ER15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1165-1171.	1.9	19
257	Clinical Application of Liver Stiffness Measurement Using Transient Elastography: A Surgical Perspective. <i>Digestion</i> , 2013, 88, 258-265.	1.2	19
258	Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment. <i>PLoS ONE</i> , 2013, 8, e52720.	1.1	19
259	Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 286-292.	1.9	19
260	Knockdown of HIF-1 $\alpha$ and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 85-95.	2.2	19
261	Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 275.	0.4	19
262	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115.	0.4	19
263	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	4.5	19
264	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635.	1.4	19
265	Liver cancer in Korea. <i>Hepatology Research</i> , 2007, 37, S106-S109.	1.8	18
266	Chronic HBV infection with persistently normal ALT b. not to treat. <i>Hepatology International</i> , 2008, 2, 185-189.	1.9	18
267	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , 2015, 35, 455-462.	1.9	18
268	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18
269	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1079-1086.	1.4	18
270	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	0.8	18



#	ARTICLE	IF	CITATIONS
271	How to Improve Treatment Outcomes for Hepatocellular Carcinoma of Intermediate and Advanced Stage. <i>Digestive Diseases</i> , 2012, 30, 598-602.	0.8	17
272	Early Predictor of Mortality due to Irreversible Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2013, 37, 1028-1033.	0.8	17
273	Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1024-1031.	1.4	17
274	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955.	1.9	17
275	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	1.9	17
276	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	2.4	17
277	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	1.3	17
278	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77.	0.9	17
279	CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 483-483.	0.8	17
280	Dynamics of the Liver Stiffness Value Using Transient Elastography during the Perioperative Period in Patients with Valvular Heart Disease. <i>PLoS ONE</i> , 2014, 9, e92795.	1.1	17
281	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275.	1.4	17
282	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , 2010, 30, 860-866.	1.9	16
283	How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements. <i>Yonsei Medical Journal</i> , 2012, 53, 337.	0.9	16
284	Antibody-Secreting Cells with a Phenotype of Ki-67low, CD138high, CD31high, and CD38high Secrete Nonspecific IgM during Primary Hepatitis A Virus Infection. <i>Journal of Immunology</i> , 2013, 191, 127-134.	0.4	16
285	Effective Biliary Drainage and Proper Treatment Improve Outcomes of Hepatocellular Carcinoma with Obstructive Jaundice. <i>Gut and Liver</i> , 2014, 8, 526-535.	1.4	16
286	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011.	1.4	16
287	Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. <i>Seminars in Oncology</i> , 2015, 42, 316-328.	0.8	16
288	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. <i>BMC Gastroenterology</i> , 2016, 16, 13.	0.8	16

#	ARTICLE	IF	CITATIONS
289	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	1.9	16
290	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	1.0	16
291	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1217-1225.	0.2	16
292	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36.	1.4	16
293	Treatment of non-resectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S424-S427.	1.4	15
294	Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , 2010, 28, 802-811.	1.0	15
295	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 882.	1.1	15
296	Identification of Proteins Indicating Radiation-induced Hepatic Toxicity in Cirrhotic Rats. <i>Journal of Radiation Research</i> , 2010, 51, 643-650.	0.8	15
297	Optimal Time for Restoring the Reliability of Liver Stiffness Measurement in Patients With Chronic Hepatitis B Experiencing Acute Exacerbation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 602-607.	1.1	15
298	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.4	15
299	Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer. <i>Virus Research</i> , 2017, 235, 86-95.	1.1	15
300	Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. <i>Cell Transplantation</i> , 2017, 26, 1059-1066.	1.2	15
301	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.2	15
302	Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 190-197.	1.3	15
303	Chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 682-684.	1.4	14
304	Normal enhanced liver fibrosis (<sc>ELF</sc>) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713.	1.9	14
305	Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 199-207.	1.4	14
306	Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242.	1.1	14

#	ARTICLE	IF	CITATIONS
307	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434.	0.4	14
308	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624.	0.6	14
309	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. <i>PLoS ONE</i> , 2019, 14, e0223678.	1.1	14
310	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	0.8	14
311	Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. <i>Radiotherapy and Oncology</i> , 2020, 152, 1-7.	0.3	14
312	Factors predictive of response to interferon- $\gamma$ therapy in hepatitis C virus type 1b infection. <i>Journal of Medical Virology</i> , 2002, 66, 481-487.	2.5	13
313	Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 847-853.	1.4	13
314	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534.	1.4	13
315	Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e35-e40.	0.7	13
316	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	0.6	13
317	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	1.0	13
318	Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 249-258.	1.9	13
319	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	1.3	13
320	Noninvasive assessment of liver fibrosis: Time to move from cross-sectional studies to longitudinal ones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1472-1473.	1.4	12
321	Positioning and Indication of Sorafenib in the Treatment Algorithm and Real Practice Setting: Western and Eastern Approach – Asian Perspective. <i>Oncology</i> , 2010, 78, 167-171.	0.9	12
322	A 96-Week Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with a Partial Virological Response to Lamivudine. <i>Antiviral Therapy</i> , 2012, 17, 1563-1570.	0.6	12
323	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1481-1491.	2.2	12
324	Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 459-465.	0.9	12

#	ARTICLE	IF	CITATIONS
325	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1348-1355.e2.	2.4	12
326	Effects of the knockdown of hypoxia inducible factor-1 $\alpha$ expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. <i>The Korean Journal of Hepatology</i> , 2010, 16, 280.	1.5	12
327	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	1.4	12
328	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	1.4	12
329	What is the role of diagnostic laparoscopy in a gastroenterology unit?. <i>Journal of Gastroenterology</i> , 2007, 42, 881-886.	2.3	11
330	Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. <i>Journal of Clinical Laboratory Analysis</i> , 2011, 25, 414-421.	0.9	11
331	Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. <i>Intervirology</i> , 2012, 55, 112-118.	1.2	11
332	Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 499-506.	0.6	11
333	Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial. <i>Yonsei Medical Journal</i> , 2012, 53, 328.	0.9	11
334	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 755.	1.0	11
335	Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 501-511.	1.4	11
336	The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years. <i>Journal of Clinical Medicine</i> , 2019, 8, 2065.	1.0	11
337	Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 132-141.	1.0	11
338	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65.	0.8	11
339	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
340	Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759.	1.1	11
341	Silencing of Hypoxia-Inducible Factor-1 $\beta$ Induces Anti-Tumor Effects in Hepatoma Cell Lines under Tumor Hypoxia. <i>PLoS ONE</i> , 2014, 9, e103304.	1.1	11
342	Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 82.	4.5	11

#	ARTICLE	IF	CITATIONS
343	A Case of Embryonal Sarcoma of the Liver Mimicking a Hydatid Cyst in an Adult. <i>Gut and Liver</i> , 2010, 4, 245-249.	1.4	11
344	Treatment of Chronic Hepatitis B in Asia-Pacific Countries: Is the Asia-Pacific Consensus Statement being followed?. <i>Antiviral Therapy</i> , 2010, 15, 607-616.	0.6	10
345	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. <i>Investigational New Drugs</i> , 2012, 30, 1150-1157.	1.2	10
346	Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. <i>Liver International</i> , 2014, 34, 1543-1549.	1.9	10
347	Transgenic mouse model expressing P53R172H, luciferase, EGFP and KRASG12D in a single open reading frame for live imaging of tumor. <i>Scientific Reports</i> , 2015, 5, 8053.	1.6	10
348	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 346-359.	4.5	10
349	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261.	4.5	10
350	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016, 22, 443-449.	4.5	10
351	Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 258-269.	0.7	9
352	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , 2014, 8, 382-394.	1.9	9
353	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2811-2813.e1.	2.4	9
354	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	1.0	9
355	A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4153-TPS4153.	0.8	9
356	Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 251.	4.5	9
357	Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 147-153.	4.5	9
358	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2015, 9, 776.	1.4	9
359	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirolgy</i> , 2008, 51, 293-298.	1.2	8
360	Clinical features and prognosis of hepatocellular carcinoma with respect to pre-C5 deletion and basal core promoter mutations of hepatitis B virus Genotype C2. <i>Journal of Medical Virology</i> , 2011, 83, 2088-2095.	2.5	8

#	ARTICLE	IF	CITATIONS
361	Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. <i>Journal of Radiation Research</i> , 2013, 54, 1069-1077.	0.8	8
362	Angled Cool-Tip Electrode for Radiofrequency Ablation of Small Superficial Subcapsular Tumors in the Liver: A Feasibility Study. <i>Korean Journal of Radiology</i> , 2016, 17, 742.	1.5	8
363	Prediction of virologic response to tenofovir mono- rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1027-1034.	2.5	8
364	An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasis). <i>Medicine (United States)</i> , 2014, 93, 1047-1054.	0.4	10
365	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , 2017, 11, 292-299.	1.9	8
366	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
367	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363.	1.1	8
368	Epidemiological and Clinical History of Viral Hepatitis in Korea. <i>Infection and Chemotherapy</i> , 2021, 53, 159.	1.0	8
369	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , 2019, 51, 1347-1356.	1.3	8
370	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2018, 12, 190-200.	1.4	8
371	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330.	1.4	8
372	Prediction of Significant Fibrosis in Chronic Hepatitis C Patients with Normal ALT. <i>Hepato-Gastroenterology</i> , 2011, 58, 1321-1327.	0.5	8
373	Association Between Polymorphism of Tumor Necrosis Factor- $\alpha$ Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2043-2048.	1.1	7
374	Casein Kinase II Inhibitor Enhances Production of Infectious Genotype 1a Hepatitis C Virus (H77S). <i>PLoS ONE</i> , 2014, 9, e113938.	1.1	7
375	The Efficacy of Endoscopic Palliation of Obstructive Jaundice in Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2014, 55, 1267.	0.9	7
376	Prevalence of mutations of hepatitis B virus affect genome replication and expression of surface antigens. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 843-850.	1.4	7
377	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. <i>Hepatology Research</i> , 2015, 45, 1331-1340.	1.8	7
378	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431.	1.1	7

#	ARTICLE	IF	CITATIONS
379	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	1.4	7
380	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502.	2.5	7
381	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	1.1	7
382	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	0.8	7
383	The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 447-55.	0.6	7
384	The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B. <i>Hepato-Gastroenterology</i> , 2010, 57, 832-8.	0.5	7
385	Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea. <i>Yonsei Medical Journal</i> , 2006, 47, 793.	0.9	6
386	Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B. <i>Digestion</i> , 2011, 84, 29-34.	1.2	6
387	Non-invasive assessment of liver fibrosis: The gap between ideal and real. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 937-939.	1.4	6
388	Acoustic radiation force impulse elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 215-216.	0.8	6
389	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671.	1.4	6
390	Prognostic Indicators for Acute Liver Failure Development and Mortality in Patients with Hepatitis A: Consecutive Case Analysis. <i>Yonsei Medical Journal</i> , 2014, 55, 953.	0.9	6
391	Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1049-1055.	1.4	6
392	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582.	0.9	6
393	Less Fibrotic Burden Differently Affects the Long-Term Outcomes of Hepatocellular Carcinoma after Curative Resection. <i>Oncology</i> , 2017, 93, 224-232.	0.9	6
394	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345.	0.4	6
395	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	1.0	6
396	High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1119-1126.	1.0	6

#	ARTICLE	IF	CITATIONS
397	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
398	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. <i>Journal of Gastroenterology</i> , 2021, 56, 570-580.	2.3	6
399	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	1.8	6
400	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	1.1	6
401	Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1023-1025.	1.4	5
402	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.1	5
403	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.4	5
404	Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 257-267.	1.1	5
405	Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-fetoprotein and <sup>18</sup> F-fluoro-2-deoxyglucose positron emission tomography. <i>Liver International</i> , 2017, 37, 592-599.	1.9	5
406	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90.	2.5	5
407	HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. <i>Rheumatology International</i> , 2018, 38, 1531-1538.	1.5	5
408	Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 108-116.	0.3	5
409	Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study. <i>Gut and Liver</i> , 2009, 3, 20-25.	1.4	5
410	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	1.4	5
411	Pro-tumorigenic roles of TGF- $\beta$ 2 signaling during the early stages of liver tumorigenesis through upregulation of Snail. <i>BMB Reports</i> , 2017, 50, 599-600.	1.1	5
412	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214.	1.4	5
413	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74.	0.4	5
414	Immunogenetics of hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S329-S332.	1.4	4



#	ARTICLE	IF	CITATIONS
415	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 144-148.	1.5	4
416	Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145.	0.9	4
417	Staging for hepatocellular carcinoma in light of tumor heterogeneity: Time to change or update?. <i>Hepatology</i> , 2018, 67, 2076-2078.	3.6	4
418	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	1.6	4
419	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	1.9	4
420	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. <i>Journal of Cancer</i> , 2020, 11, 2442-2452.	1.2	4
421	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	0.8	4
422	Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. <i>Blood</i> , 2011, 118, 2232-2232.	0.6	4
423	Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model. <i>Digestive Diseases and Sciences</i> , 2016, 61, 507-516.	1.1	3
424	Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes. <i>Journal of Medical Virology</i> , 2017, 89, 146-152.	2.5	3
425	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
426	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. <i>PLoS ONE</i> , 2020, 15, e0232186.	1.1	3
427	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	1.2	3
428	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. <i>Gut and Liver</i> , 2021, 15, 895-903.	1.4	3
429	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105.	1.1	3
430	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 125-135.	4.5	3
431	The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea. , 2000, , 1-9.		3
432	The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 62715-62725.	0.8	3

#	ARTICLE	IF	CITATIONS
433	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3
434	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. <i>Digestion</i> , 2012, 86, 264-272.	1.2	2
435	Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Digestion</i> , 2013, 87, 196-203.	1.2	2
436	Clonal evolution of multidrug resistant hepatitis <scp>B</scp> virus during entecavir rescue therapy. <i>Liver International</i> , 2015, 35, 2370-2383.	1.9	2
437	A 96â€week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 865-871.	1.4	2
438	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544.	0.8	2
439	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	0.8	2
440	Differences in presentation and management patterns in patients with hepatocellular carcinoma (HCC): Data from HCC registry in Asia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 229-229.	0.8	2
441	Characteristics and Survival of Korean Patients with Hepatocellular Carcinoma: A Nationwide Random Sample Study. <i>Journal of Liver Cancer</i> , 2014, 14, 97-107.	0.3	2
442	Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 399.	4.5	2
443	Treatment of Hepatocellular Carcinoma With Lenvatinib. <i>Gastroenterology and Hepatology</i> , 2018, 14, 662-664.	0.2	2
444	The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. <i>Journal of Medical Virology</i> , 2016, 88, 820-827.	2.5	1
445	Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon- $\alpha$ therapy. , 1996, 49, 95.		1
446	Hepatitis B viral load to predict survival of HCC patients treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2014, 32, 188-188.	0.8	1
447	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 345-345.	0.8	1
448	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.. <i>Journal of Clinical Oncology</i> , 2019, 37, 316-316.	0.8	1
449	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
450	Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 26-31.	0.4	1

#	ARTICLE	IF	CITATIONS
451	Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1585-1586.	1.4	0
452	Impact of a shortened surveillance interval on hepatocellular carcinoma survival. Hepatic Oncology, 2014, 1, 3-5.	4.2	0
453	Reply. Hepatology, 2016, 63, 672-673.	3.6	0
454	Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. , 2021, , 277-283.		0
455	Early radiotherapy versus late radiotherapy after incomplete transarterial chemoembolization in hepatocellular carcinoma.. Journal of Clinical Oncology, 2015, 33, 459-459.	0.8	0
456	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. Journal of Clinical Oncology, 2017, 35, e15678-e15678.	0.8	0
457	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0
458	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0
459	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0
460	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. , 2020, 15, e0232186.		0